АЛЬФА-ИНТЕРФЕРОН В КЛИНИЧЕСКОЙ ПРАКТИКЕ

Now in an arsenal of applied medicine the worthy place is occupied with preparations of interferons. And it is no wonder. Interferons as natural factors of nonspecific protection of an organism and mediators of immunity possess the widest spectrum of action. Interferons represent family of cytokines of the mediators playing the important role in formation of immunity and possessing expressed antiviral, antimicrobic, radio protective and immune action. The problem of clinical application of interferons is actual for a wide range of experts, including clinicians, and also doctors of practical public health services. Increasing interest of doctors of different specialties to this problem is caused not only high efficiency of application of preparations, but also steady growth of number of the patients, suffering by virus, infectious, oncologic diseases.

1. Волкова М.А. Гематол. и трансфузиол. 1999. Т 44, № 4. С. 32–36.

2. Ершов Ф.И. Вопр. вирусол. 1998. № 6. С. 247–252.

3. Ершов Ф.И. Система интерферона в норме и при патологии. М.: Медицина, 1996. 240 с.

4. Зарецкая Ю.А. Клиническая иммуногенетика. М., 1983.

5. Козинец Г.И. Кровь и инфекция / Г. И. Козинец, В. В. Высоцкий, В. М. Погорелов // М., 2001.

6. Кузнецов В.П. Иммунология. 1987. № 4. С. 30–34.

7. Лукина Е.А. Система мононуклеарных фагоцитов и биологические эффекты провоспалительных цитокинов // Росс. журн. гастроэнтерол., гепатол., колопроктол. 1998. Т. 8, № 5. С. 7–13.

8. Механизмы иммунного «ускользания» при вирусных гепатитах / В.Т. Ивашкин, С.Н. Маммаев, А.О. Буеверов и др. // Росс. журн. гастро энтерол., гепатол., колопроктол. 2000. Т. 10, № 5. С. 7–13.

9. Серов В.В. Морфологические критерии оценки этиологии, степени активности и стадии процесса при вирусных хронических гепатитах В и С. / В.В. Серов, Л.О. Севергина // Арх. патол. 1996. № 4. С. 61–64.

10. Щегловитова О.Н. Вопр. вирусол. 1999. № 2. С. 52–54.

11. Elias J.A., Kotloff R. Mononuclear cell-fibroblasts interactions in the human lung // Chest. 1991. Vol. 99, № 3. P. 73–79.

12. Friedman S. The cellular basis hepatic fibrosis mechanisms and treatment strategies / S. Friedman // New Eng. J. 1993. Vol. 328. P. 1828–1835.

13. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis interventional therapy group / J. McHutchison, S. Gordon, E. Schiff et al. // N. Engl. J. Med. 1998. Vol. 339. P. 1485–1492.

14. Nuovo G.J. Histologic distribution of hepatitis А, В, C, D, E, and G with concomitant cytokine response in liver tissue / G.J. Nuovo // Diagn. Mol. Pathol. 1998. Vol. 7, № 5. P. 267–275.

15. Romero R. Cytokine inhibition of the hepatitis D virus core promoter / R. Romero, J. E. Lavine // Hepatology. 1996. Vol. 23, № 1. P. 17–23.

16. Sen G.C. Interferon-induced antiviral actions and their regulation / G.C. Sen, R.M. Ransohoff // Adv. Virus. Res. 1993. Vol. 42. P. 57–102.

17. Serum levels of soluble tumor necrosis factor receptors and effects therapy in patients with chronic hepatitis С virus infection / Y. Itoh, T. Okanoue, N. Ohnishi et al. // Am. J. Gastroenterol. 1999. Vol. 94. P. 1332–1340.

18. TNF-a, inhibits liver collagen-al (I) gene expression through a tissuespecific regulatory region / K. Houglum, M. Buck et al. // Am. J. Physiol. 1998. Vol. 37. P. 840–847.

19. Viral and host factors in the prediction of response to interferon-alpha therapy in chronic hepatitis С after long-term follow-up / P. Knolle, S. Kremp, T. Hohler et al. // J. Viral Hepat. 1998. Vol. 5. P. 399–406.

20. Zein N.N. Interferon’s in the management of viral hepatitis / N.N. Zein // Cytokines Cell. Mol. Ther. 1998. Vol. 4. P. 229–241.